Andrew Pollack

New York Times

Guest

Correspondent for the New York Times, covering the business and science of biotechnology

Andrew Pollack on KCRW

Mylan might or might not have good news for people who need EpiPens.

Drug-maker Mylan and its $300 "generic" EpiPen

Mylan might or might not have good news for people who need EpiPens.

from To the Point

Specialists who treat rare diseases are protesting gigantic increases in the prices of old and familiar drugs. The cost of one medicine jumped 5000 percent -- overnight.

When Drug Prices Skyrocket Overnight

Specialists who treat rare diseases are protesting gigantic increases in the prices of old and familiar drugs. The cost of one medicine jumped 5000 percent -- overnight.

from To the Point

ZMapp is an experimental drug that has shown promise as a treatment for the Ebola virus.

The Ebola Drug

ZMapp is an experimental drug that has shown promise as a treatment for the Ebola virus.

from Press Play with Madeleine Brand

More from KCRW

Was there a message behind the unanimous SCOTUS ruling on Trump’s eligibility to appear on the ballot? What’s driving a global trend toward authoritarian leaders?

from Left, Right & Center

Juan Cole, a renowned history professor at the University of Michigan and expert on the Middle East and South Asia, joins host Robert Scheer on this episode of the Scheer Intelligence…

from Scheer Intelligence

This fall, women lawmakers are slated to make up the majority in the California Legislature — a historical first. They could lead on reproductive care and family leave.

from KCRW Features

The race for two open supervisor seats is heating up in Orange County. Two candidates might compete in the November run-off election if no one receives more than 50% of votes.

from KCRW Features

On Thursday, March 7, President Biden will deliver the State of the Union address to a Joint Session of Congress. Tune into KCRW to follow along NPR's live coverage at 6 p.m. PST.

What lasting impact will Mitch McConnell leave on Senate leadership? Plus, will Biden or Trump change their tune on compromise at the border?

from Left, Right & Center

Join KCRW and NPR as the Supreme Courts hears arguments over the Colorado State Supreme Court's decision to disqualify former President Donald Trump from the state's primary ballot.

A committee wants to invest in the happiness of Californias with data-proven ideas. But a multi-billion dollar state budget deficit looms over their efforts.

from KCRW Features

Though votes are still being tallied, LA Magazine Reporter Jon Regardie weighs in on which LA races will go to a run-off in November and which saw early wins.

from KCRW Features